NCT07581496招募中不适用
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
University Hospital, Basel, Switzerland2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2025年6月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 35
- 试验地点
- 2
研究概览
简要总结
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.
Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality.
Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients > 18 years of age, able to give informed consent as documented by signature,
- •patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B
排除标准
- •Patients with metastases or concomitant upper tract tumor at diagnosis will
- •Patients with non T1 G3 cancers
- •Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy
- •Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
- •Vulnerable persons (e.g. < 18y of age, unable to consent to the study)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
A Phase 3, Open label, Randomized and Controlled Study of Disitamab Vedotin with Pembrolizumab Versus platinum containing chemotherapy in participants with Urothelial cancer that Expresses HER2 that has spread through the body or spread near where it started.CTRI/2025/07/091091Seagen Inc., a wholly owned subsidiary of Pfizer400
尚未招募
不适用
Tumor Budding and T1 Substaging in Urothelial Bladder CancerUrothelial Bladder CarcinomaNon-Muscle-Invasive Bladder Cancer (NMIBC)Muscle-Invasive Bladder Cancer (MIBC)Bladder CarcinomaNCT07529639Assiut University100
招募中
2 期
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderNCT07475806Astellas Pharma Global Development, Inc.240
尚未招募
不适用
A clinical trial to study the effects of performing and omitting a restage transurethral resection of bladder tumour in patients with non-muscle invasive bladder tumours.CTRI/2024/12/078306AIIMS, NEW DELHI84
招募中
2 期
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaLow Grade Upper Tract Urothelial CarcinomaNCT07265947Tyra Biosciences, Inc230